Amarantus Bioscience Holdings, Inc. - FORM 8-K - EX-3.2 - AMENDMENT TO CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E 12% CONVERTIBLE PREFERRED STOCK. - February 24, 2016

Attached files

file filename
EX-10.1 - FORM OF SECURITIES PURCHASE AGREEMENT - Amarantus Bioscience Holdings, Inc.f8k021916ex10i_amarantus.htm
EX-99.1 - AMARANTUS BIOSCIENCE HOLDINGS, INC. PRESS RELEASE, DATED FEBRUARY 19, 2016 - Amarantus Bioscience Holdings, Inc.f8k021916ex99i_amarantus.htm
EX-10.4 - FORM OF PLACEMENT AGENCY AGREEMENT DATED FEBRUARY 19, 2016 - Amarantus Bioscience Holdings, Inc.f8k021916ex10iv_amarantus.htm
EX-10.2 - FORM OF WARRANT - Amarantus Bioscience Holdings, Inc.f8k021916ex10ii_amarantus.htm
EX-3.1 - AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES H 12% CONVERTIBLE PREFERRED STOCK - Amarantus Bioscience Holdings, Inc.f8k021916ex3i_amarantus.htm
EX-10.3 - FORM OF LEAK-OUT AGREEMENT DATED FEBRUARY 19, 2016 BETWEEN THE COMPANY AND CERTAIN HOLDERS OF THE COMPANY'S SERIES E CONVERTIBLE PREFERRED STOCK, SERIES H CONVERTIBLE PREFERRED STOCK AND FIVE YEAR COMMON STOCK PURCHASE WARRANTS - Amarantus Bioscience Holdings, Inc.f8k021916ex10iii_amarantus.htm
8-K - CURRENT REPORT - Amarantus Bioscience Holdings, Inc.f8k021916_amarantus.htm

Exhibit 3.2

 

CERTIFICATE OF AMENDMENT OF

CERTIFICATE OF DESIGNATION OF

AMARANTUS BIOSCIENCE HOLDINGS, Inc.

Pursuant to Section 78.1955 of the

Nevada Revised Statutes

 

 

 

SERIES E CONVERTIBLE PREFERRED STOCK

 

On behalf of Amarantus BioScience Holdings, Inc., a Nevada corporation (the “Corporation”), the undersigned hereby certifies that the following resolution has been duly adopted by the board of directors of the Corporation (the “Board”):

 

RESOLVED, that, pursuant to the authority granted to and vested in the Board by the provisions of the articles of incorporation of the Corporation (the “Articles of Incorporation”):

 

1.Section 6(a) of the Second Amended and Restated Certificate of Designation of the Corporation for the Series E Convertible Preferred Stock shall be modified by adding the following sentence to the end of Section 6(a):

 

“Notwithstanding the foregoing, none of the Preferred Stock may be converted until March 31, 2016.”

 

IN WITNESS WHEREOF, the undersigned have duly signed this Certificate of Amendment to the Certificate of Designation of the Series E Convertible Preferred Stock as of this 22nd day of February 2016.

 

  Amarantus BioScience Holdings, Inc.
   
  /s/ Gerald Commissiong
 

By:    Gerald Commissiong

Title: Chief Executive Officer

 

Amarantus Bioscience Holdings, Inc. Reports